Home / People / Sarah Hanson
Portrait ofSarah Hanson

Sarah Hanson

Partner
Co-Head of the CMS Life Sciences & Healthcare Group

Contact
CMS Cameron McKenna Nabarro Olswang LLP
Cannon Place
78 Cannon Street
London
EC4N 6AF
United Kingdom
Languages English
Life Sciences & Healthcare

Sarah Hanson is Global Co-Head of the CMS Life Sciences & Healthcare Group. In this position, she jointly leads an international team of more than 480 lawyers, patent attorneys, scientists and academics’ across CMS. Sarah was formerly the Co-Head of the Life Sciences & Healthcare Sector Group for CMS Cameron McKenna Nabarro Olswang LLP. 

She has specialised in high value, cross-border commercial, intellectual property and outsourcing transactions for more than 20 years having advised on a broad range of commercial agreements relating to in and out licensing, sales and distributor arrangements, research and development, manufacturing and supply, strategic alliances and joint ventures. During her time with the firm she has been on secondment with Warner Lambert (now part of Pfizer). 

more less

"Sarah Hanson is an excellent commercial lawyer, especially when it comes to extremely complex matters."

Chambers, 2023

"Ranked a Global Leader in Life Sciences - Transactional"

Who’s Who Legal 2022

Sarah Hanson is ranked in Chambers and Partners for Life Sciences: Transactional with Chambers reporting that Sarah ‘has acted on some of the most iconic deals of recent times’ and client feedback including "Sarah Hanson has deep topic and matter expertise in life sciences." "Sarah is really good and clients really like her."

Chambers, 2022

Sarah Hanson is ranked in Legal 500 and client feedback includes "Sarah Hanson – responsive to enquiries and pragmatic advice provided."

Legal 500, 2021

"Sarah is 'a fantastic client care partner’ and is ranked as a Leading Individual in Legal 500, 2021 for Life Sciences and Healthcare."

Legal 500, 2021

Sarah is ranked in Chambers and Partners for Life Sciences: Transactional with a client reporting "We get fast and clear responses from her and good engagement at all stages. We have had a very positive overall experience."

Chambers

"Sarah Hanson has acted as our relationship partner and has always responded quickly and helped to select appropriate advisors within the CMS network for each instruction."

Client Feedback, Legal 500

Ranked as a Leading Individual for Commercial Contracts.

Legal 500, 2019

Relevant experience

  • Essential Pharmaceuticals, a pharma business, on the sale to Rosemont Pharmaceuticals of its oral liquids portfolio of products and the acquisition from Rosemont Pharmaceuticals of a portfolio of products, in each case through a suite of agreements including product rights agreements, supply agreements, IP licences and quality agreements.
  • Almirall SA on the transfer of its respiratory franchise to AstraZeneca for an initial consideration of USD 875m on completion and up to USD 1.22bn in development, launch and sales related milestone payments.
  • PGT Healthcare LLP in relation to a collaboration with Swisse Wellness Group Party Limited in relation to vitamin, mineral and food supplement products across certain territories.
  • Sinclair IS Pharma plc on an exclusive 100 year distribution arrangement with an affiliate of Valeant Pharmaceuticals International, Inc, for injectable aesthetic dermal filler products in Western Europe.
  • Takeda Pharmaceutical on its EUR 9.6bn (debt-free cash free) acquisition of Swiss drug company, Nycomed.
  • Futura Medical, an AIM listed company, in relation to the licensing of its CSD500 product to major pharmaceutical and healthcare group, including Church & Dwight and Ansell.  We have advised on the commercial agreements with contract manufacturers and own brand labellers as well as the associated technical and quality agreements.
  • On the establishment of the Francis Crick Institute, a consortium of Cancer Research UK, the MRC, UCL and the Wellcome Trust, as a world leading establishment for medical research and innovation at Kings Cross, London, together with ongoing operational advice.
  • Nestlé Health Science on its licence agreement with Lipid Therapeutics for exclusive rights to develop and commercialise a new therapeutic for treating mild to moderate ulcerative colitis.
  • hVIVO plc, an AIM listed company, on its interests in PrEP Biopharm and also on PrEP Biopharm’s licensing arrangements with Janssen Pharmaceuticals with respect to technologies to be developed and commercialised for the treatment of a variety of respiratory viruses.
  • Bayer Crop Science in relation to the sale of its Norwich based manufacturing business (now Briar Chemicals Limited) to the Aurelius Group.
  • Chugui Pharma Marketing in relation to the license of exclusive commercialisation rights to Swiss based Helsiun group’s innovative ghrelin receptor agonist, anamorelin, for the three major European  pharmaceutical markets.
  • Syncona on its collaboration with the University of Edinburgh Centre for Regenerative Medicine and subsequent establishment and licensing of technology to Resolution Therapeutics.
  • Contura on the divestment of its rights to the Bulkamid product for up to $235m together with the associated manufacturing agreement for supply of Bulkamid with rights to a technology transfer.
  • CooperSurgical on the purchase of Safe Obstetric Systems, the manufacturer of the Fetal Pillow.
  • The shareholders of the Essential Group on its disposal to Gyrus Capital.
     
more less

Memberships & Roles

  • ABHI
  • ABPI
  • Biotech Industry Association
  • Society for Computers & Law
  • TechUK
more less

Publications

  • European Biopharmaceutical Review – eHealth opportunities for the biopharmaceutical industry
more less

Lectures list

  • EU Pharma Law Conference
more less

Education

  • 2004 – Intellectual Property Diploma, Bristol University, Bristol
  • 1994 – Distinction, The College of Law, LPC, Chester
  • 1993 – BA (Hons) Cantab Law 2:1, St John’s College, Cambridge
more less
TMT - Technology, Media & Telecommunications

Sarah Hanson is a Partner in the technology team and is a representative on the management committee of the CMS Commercial Law Group as well as being an active member of the firm’s Technology, Media and Communications sector group.

Sarah Hanson is a Co-head of the Life Sciences & Healthcare Sector Group for CMS Cameron McKenna Nabarro Olswang LLP. 

She has specialised in high value, cross-border commercial, intellectual property and outsourcing transactions for more than 20 years having advised on a broad range of commercial agreements relating to in and out licensing, sales and distributor arrangements, research and development, manufacturing and supply, strategic alliances and joint ventures.  She also provides data privacy advice to clients on a broad range of issues.

more less

"Sarah Hanson is an excellent commercial lawyer, especially when it comes to extremely complex matters."

Chambers, 2023

"Ranked a Global Leader in Life Sciences - Transactional"

Who’s Who Legal 2022

Sarah Hanson is ranked in Legal 500 and client feedback includes "Sarah Hanson – responsive to enquiries and pragmatic advice provided."

Legal 500, 2021

Sarah Hanson is ranked in Chambers and Partners for Life Sciences: Transactional with Chambers reporting that Sarah ‘has acted on some of the most iconic deals of recent times’ and client feedback including "Sarah Hanson has deep topic and matter expertise in life sciences." "Sarah is really good and clients really like her."

Chambers, 2022

"Sarah is 'a fantastic client care partner’ and is ranked as a Leading Individual in Legal 500, 2021 for Life Sciences and Healthcare."

Legal 500, 2021

Ranked as a Leading Individual for Commercial Contracts.

Legal 500, 2019

Relevant experience

  • A retail company in relation to a comprehensive IT transformation project with a value of between GBP 1-2bn.  The new IT operating model involves the appointment of a ‘service integrator’ supplier who will manage and integrate all IT services.  The project also involves appointment of multiple IT “service tower” providers.  This includes the following IT services: (i) End User Computing services; (ii) Network services (telecoms networks across company’s entire estate); (iii) Front Office services (front office IT applications including cash and stock management, retail and stock sales, branch accounting); and (iv) Back Office services (back office IT applications including HR, accounting and finance systems).
  • Camelot in respect of the establishment of the Euro Millions lottery and related matters.
  • A global company on its transformative HR outsourcing to deliver a new technology platform and service delivery model across multiple regions.
  • A healthcare company on the adoption of RFID technology to support the management of the supply chain for the distribution of its products from the manufacturer to end users.
  • An international consumer brands company on its bid for the Boots Consumer Healthcare division including structuring various IP licences and manufacturing arrangements.
  • A well-known consumer products company in the outsourcing of its back office IT functions to a major IT provider.
  • A marketing company in relation to a number of contracts with a major supermarket for the design and implementation of various consumer product campaigns.
  • A UK listed company on the agency agreements to be entered into by it with various distributors across Europe.
  • A household name drinks company on the logistics and warehousing arrangements for the supply of products in Europe. 
  • A major retail company on various matters including advising on the terms and conditions for its Christmas catalogue, the supply arrangements with a significant procurer of goods and the establishment of its gift voucher scheme.
more less

Memberships & Roles

  • ABHI
  • ABPI
  • Biotech Industry Association
  • Society for Computers & Law
  • TechUK
more less

Publications

  • European Biopharmaceutical Review – eHealth opportunities for the biopharmaceutical industry
more less

Lectures list

  • EU Pharma Law Conference
more less

Education

  • 2004 – Intellectual Property Diploma, Bristol University, Bristol
  • 1994 – Distinction, The College of Law, LPC, Chester
  • 1993 – BA (Hons) Cantab Law 2:1, St John’s College, Cambridge
more less

Feed

12/03/2024
Life Science Fundamentals
We are delighted to invite you to our new Life Science Fundamentals workshops, 2024. The workshops will take place in-person at our Cannon Place, London office and will be followed by lunch and an opportunity...
03/01/2024
CMS Life Sciences & Healthcare Global Brochure
With big deals fuelling record levels of M&A activity, a steady stream of innovative and disruptive technologies, new and increasingly complex regulatory challenges and a thriving start-up community...
18/12/2023
Digital health apps and telemedicine in Singapore
Digital Health Apps/Software 1. How is the software within digital health apps classified in your jurisdiction, and what regulation(s) apply? 1.1 Is it considered a “medical device” or a “product”...
Comparable
08/12/2023
COP28 Update – 8 December 2023
COP28 has seen a host of pledges and agreements, and the CMS team has been reflecting on the announcements and sharing their experiences of COP28 on the CMS COP28 Hub. Here, we roundup the latest commentary...
08/12/2023
COP28: Global Health Under the Spotlight
Health took centre stage at the first ever ‘Health Day’ at COP28 on 3 December. The program focused the attention of world leaders on the profound public health-related issues stemming from climate...
22/11/2023
DHSC and ABPI agree 2024 voluntary scheme for branded medicines pricing,...
The 2024 voluntary scheme for branded medicines pricing, access and growth (“VPAG”) provides for accelerated growth of the NHS’s annual branded medicines spend, introduces differentiated reimbursement...
09/11/2023
CMS Life Sciences Vital Signs, Winter 2023
2023 has seen some significant legal developments impacting the life sciences industry, and as we look ahead to 2024, there are several important developments which we would like to keep our clients informed...
08/11/2023
CMS Life Sciences Vital Signs, Winter 2023
2023 has seen some significant legal developments impacting the life sciences industry, and as we look ahead to 2024, there are several important developments which we would like to keep our clients informed...
14/09/2023
CMS - In View: Life Sciences & Healthcare update webinar
CMS is delighted to invite you to the next instalment of our Life Sciences & Healthcare update webinar, where experts from across the firm discuss key industry topics impacting, innovating and disrupting...
12/09/2023
UK Re-joins Horizon Europe
On 7 September, the UK re-joined the world’s largest research collaboration programme, Horizon Europe. The decision has been welcomed by academics and life sciences businesses within the UK and the...
25/08/2023
Life Sciences & Healthcare
Then there is the extent to which all other NHS procurement will be subject to Procurement Act, and the specific features of the Act that will be relevant to healthcare procurement. These include: the scope of the ‘light touch regime’; new rules on frameworks and ‘dynamic markets’; debarment and exclusion; contract management and modifications; transparency rules including the publication of different forms of notices). Our sector-specific insights will help you understand and navigate these new rules and their specific application in the sector.   
28/06/2023
UK announces £21m AI roll-out across NHS
IntroductionOn 23 June 2023, the UK government announced a £21 million fund aimed at accelerating the deployment of Artificial Intelligence (“AI”) across the National Health Service (“NHS”)...